Group 1: Strategy and Market Overview - The report emphasizes the importance of combining momentum strategies with quarterly report trading for April, suggesting that timing and industry selection can enhance strategy performance [3] - A review of the A-share market indicates a rebound after a dip, influenced by geopolitical tensions and global market fluctuations [3][4] - The report highlights the performance of various asset classes, noting that commodity prices have generally risen, while the U.S.-China interest rate spread has expanded [3] Group 2: Fixed Income Insights - The report tracks a significant drop in pig prices, reaching a new low, indicating a challenging environment for the agricultural sector [5] - The "fixed income plus" products are facing redemption pressures, which may lead to a reduction in equity asset allocations and widening of yield spreads [6] Group 3: Industry-Specific Insights - In the machinery and equipment sector, the demand for motor winding equipment is expected to surge due to the growth of the robotics industry, with market size projected to grow from 0.7 billion to 13.5 billion by 2030 [7][8] - The coal industry is experiencing price fluctuations due to geopolitical tensions affecting LNG supplies, with increased reliance on coal for power generation expected to support global coal prices [13][14] - The pig farming sector is facing significant losses, with prices dropping to 9.46 yuan/kg, and the report suggests that the industry will continue to struggle in the near term [17][18] Group 4: Company Performance Highlights - China Merchants Bank reported a slight increase in revenue and net profit for 2025, with a focus on wealth management and stable asset quality [24][25][28] - Meituan's core local business is entering a profit recovery phase as competition in the food delivery sector eases [29] - Huakong Technology achieved substantial revenue growth in 2025, driven by its strategic upgrade of the "3+N+3" smart product platform [30] Group 5: Investment Recommendations - The report recommends focusing on companies in the coal sector such as China Coal Energy and Yanzhou Coal Mining, which are expected to benefit from the current market dynamics [15] - In the agricultural sector, it suggests monitoring companies like Muyuan Foods and Wens Foodstuffs for potential investment opportunities despite current losses [17][18] - For the machinery sector, it highlights the investment potential in Tianzhong Precision Machinery, which has a strong technological foundation in motor winding equipment [8]

Investment Rating - The report maintains a positive outlook on the Chinese innovative drug industry chain, highlighting the potential for growth driven by business development (BD), policy support, and clinical advancements [1]. Core Insights - The innovative drug BD authorization total exceeded $60 billion in Q1 2026, indicating accelerated realization of global collaboration value. In 2025, the total transaction amount for Chinese innovative drug BD reached a historical high of $135.655 billion, with 157 transactions [2][11]. - The government has upgraded its strategic positioning of the biopharmaceutical sector, now recognized as a "new emerging pillar industry" in the 2026 government work report. This includes the establishment of a multi-layered payment system for innovative drugs [2][15]. - Clinical activity is on the rise, with China leading globally in the number of innovative drugs under development, accounting for 33.7% of the total. By the end of 2025, 827 original innovative drugs entered clinical trials, representing 47.4% of the global total [2][16][19]. Market Observation - The pharmaceutical and biotechnology sector saw a weekly increase of 1.56%, ranking 4th out of 31 sectors, while year-to-date, the sector has declined by 1.38%, ranking 17th [1][10]. Company Dynamics - **Insilico Medicine**: Announced a collaboration with Eli Lilly, with an upfront payment of $115 million and a total deal value potentially reaching $2.75 billion, validating the commercial value of its AI drug development platform [3][23]. - **Kangfang Biopharma**: Reported a revenue of 3.056 billion yuan in 2025, a 43.9% increase year-on-year, driven by the commercialization of its core dual-antibody products [3][24]. - **Innovent Biologics**: Achieved a total revenue of 13.042 billion yuan in 2025, a 38.4% increase, marking its first time surpassing 10 billion yuan in revenue and returning to profitability [3][25]. - **Kolin Biotech**: Generated revenue of 2.058 billion yuan in 2025, a 6.5% increase, with its core ADC product contributing to its commercial growth [3][26]. - **Ascletis Pharma**: Reported a total revenue of 7.731 billion yuan in 2025, a 16.5% increase, with innovative drugs accounting for 81.5% of its revenue [3][27]. - **Zymeworks**: Achieved revenue of 269.6 million yuan in 2025, with a strong cash reserve of 919 million yuan, supporting its global expansion plans [3][28].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights a strong recovery in the biopharmaceutical sector, with significant growth in the "WuXi" companies, indicating a return to a prosperous cycle driven by increased demand and order expansion [4][34] - The report emphasizes the structural growth in the industry, particularly in preclinical services and small molecule CDMO, which are expected to accelerate in 2026 [5][36] Summary by Sections 1. "WuXi" Companies Performance - WuXi AppTec achieved a revenue of 45.46 billion RMB in 2025, a year-on-year increase of 15.8%, with a net profit of 19.15 billion RMB, reflecting a 102.7% increase [13] - WuXi Biologics reported a revenue of 21.79 billion RMB, up 16.7%, and a net profit increase of 45.3% [18] - WuXi STA's revenue grew by 46.7%, with a net profit increase of 69.9%, indicating strong order growth and demand recovery [26] 2. Growth Outlook for 2026 - WuXi AppTec expects a revenue growth of 18-22% for its continuing operations in 2026, with capital expenditures projected to rise to 6.5-7.5 billion RMB [4][35] - WuXi Biologics anticipates a revenue increase of 13-17% in 2026, factoring in currency fluctuations [34] - WuXi STA aims for a CAGR of 30-35% from 2025 to 2030, indicating robust growth potential [34] 3. Structural Growth Trends - The preclinical CRO sector is showing signs of recovery, with WuXi AppTec's testing services returning to positive growth and significant order increases in preclinical services [5][34] - Small molecule CDMO is expected to accelerate growth in 2026, driven by increased demand for GLP-1 class drugs [36] - ADC/XDC/TIDES CDMO sectors are maintaining high growth rates, with WuXi STA projecting a 25% CAGR over the next five years [38] 4. Market Performance - The biopharmaceutical sector rose by 1.56% in March 2026, outperforming the CSI 300 index by 2.97 percentage points [39] - The medical R&D outsourcing sector saw the largest gains, while the blood products sector experienced the most significant decline [40]

Investment Rating - The report maintains a "Market Weight" rating for the pharmaceutical and biotechnology industry, indicating an expected performance in line with the market index over the next six months [5][30]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 5.06% from March 13 to March 26, 2026, which is approximately 0.6 percentage points lower than the index [4][15]. - All sub-sectors within the industry recorded negative returns during the same period, with the medical research outsourcing and in vitro diagnostics sectors experiencing the least decline at 1.97% and 2.84%, respectively. The hospital and blood products sectors had the largest declines at 7.71% and 6.95% [4][16]. - Approximately 17% of stocks in the industry recorded positive returns, while around 83% experienced negative returns during the reporting period [17][20]. - The overall price-to-earnings (P/E) ratio for the SW pharmaceutical and biotechnology industry was approximately 44.86 times as of March 26, 2026, which reflects a decrease in industry valuation [21][30]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a decline of 5.06% from March 13 to March 26, 2026 [15]. - All sub-sectors recorded negative returns, with the least affected being medical research outsourcing and in vitro diagnostics [16]. - About 17% of stocks in the industry had positive returns, with the highest gainers and losers identified [20]. 2. Industry News - A significant procurement event occurred on March 24, 2026, regarding the centralized procurement of coronary intervention balloon medical consumables, which attracted attention due to its innovative pricing strategy [28]. - The National Health Commission issued guidelines for evaluating the clinical application of medical technologies, emphasizing the importance of quality and safety in healthcare [25][27]. 3. Company Announcements - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. announced receiving a CEP certificate for its sulfanilamide raw material, indicating compliance with European quality standards [29]. 4. Industry Outlook - The report suggests that the investment risk-reward ratio for the innovative drug sector is improving, with several companies expected to exceed performance expectations during the earnings disclosure period [30][32]. - Recommended stocks for investment include leading companies across various segments such as medical devices, pharmaceutical commerce, aesthetic medicine, and innovative drugs [32][33].

Investment Rating - The report maintains a "Market Weight" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [25][31]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 5.06% from March 13 to March 26, 2026, which is approximately 0.6 percentage points lower than the index [10][11]. - All sub-sectors within the industry recorded negative returns during the same period, with the medical research outsourcing and in vitro diagnostics sectors experiencing the least decline at 1.97% and 2.84%, respectively. The hospital and blood products sectors had the largest declines at 7.71% and 6.95% [11][12]. - Approximately 17% of stocks in the industry recorded positive returns, while about 83% experienced negative returns during the reporting period [12][15]. - The overall price-to-earnings (P/E) ratio for the SW pharmaceutical and biotechnology industry was approximately 44.86 times as of March 26, 2026, which indicates a decrease in industry valuation [16][25]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry lagged behind the CSI 300 index, with a decline of 5.06% from March 13 to March 26, 2026 [10]. - All sub-sectors recorded negative returns, with the medical research outsourcing and in vitro diagnostics sectors showing the smallest declines [11]. - About 17% of stocks in the industry had positive returns, with the top performer being Meinuohua, which increased by 54.47% [12][15]. 2. Industry News - A significant event was the announcement of the results for the centralized procurement of coronary intervention balloon medical consumables in Henan, which saw all participating companies selected, reflecting a shift towards a "price anchor" concept [23]. - The National Health Commission issued guidelines for evaluating the clinical application of medical technologies, emphasizing the importance of quality and safety in healthcare [20][22]. 3. Company Announcements - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. received a CEP certificate for its sulfanilamide raw material, indicating compliance with European quality standards. The market size for this product in China is approximately 428 million RMB, with a year-on-year growth of 3.1% [24]. 4. Weekly Industry Perspective - The report suggests that the investment risk-reward ratio for the innovative drug sector is improving, with several companies expected to exceed performance expectations during the earnings disclosure period. Key sectors to watch include medical devices, pharmaceutical commerce, aesthetic medicine, scientific services, hospital and diagnostic services, traditional Chinese medicine, innovative drugs, biological products, and CXO services [27][28].

Investment Rating - The report maintains an "Accumulate" rating for the industry [7] Core Insights - The medical and biological sector has experienced a decline of 2.77% from March 16 to March 22, ranking 8th out of 31 sectors, and a year-to-date decline of 2.90%, ranking 20th out of 31 sectors [1][11] - The disposable glove sector is entering a price increase window due to rising costs driven by raw material prices, particularly for nitrile gloves, which are influenced by international oil prices and basic chemical prices [2][12] Industry Dynamics - The primary raw materials for disposable gloves are sourced from the petrochemical system, with costs closely tied to international oil prices. Recent increases in the prices of butadiene (up 19.6%) and acrylonitrile (up 10.3%) have significantly raised the cost of nitrile latex, which saw a price increase of approximately 16.7% in the North China market [2][12][12] Company Dynamics - **Xinnoway**: Achieved revenue of 2.158 billion yuan in 2025, a year-on-year increase of 8.93%. The biopharmaceutical segment saw a revenue increase of 192.65% [3][13] - **Deqi Pharmaceuticals**: Reported revenue of 105 million yuan in 2025, a 14.5% increase. The company has made progress in its core products and secured a global exclusive licensing agreement for ATG-201, receiving an upfront payment of 80 million USD [4][14] - **Laikai Pharmaceuticals**: Generated revenue of 107 million yuan in 2025, primarily from the licensing of LAE002. The company is advancing its obesity and oncology pipelines [5][15] - **China Resources Sanjiu**: Achieved revenue of 31.603 billion yuan in 2025, a 14.43% increase, and net profit of 3.421 billion yuan, a 1.58% increase. The company completed the acquisition of a 28% stake in Tian Shi Li, enhancing its business structure [6][17] Suggested Focus Areas - The report suggests paying attention to the innovative drug industry chain [5][18]

Investment Rating - The report maintains an "Increase" rating for the pharmaceutical sector [5] Core Insights - The pharmaceutical sector has experienced a decline of 2.78% this week, ranking 17th out of 31 sectors, while it has seen a slight increase of 0.1% year-to-date, ranking 24th out of 31 [9] - The 2026 government work report emphasizes the importance of the biopharmaceutical industry, categorizing it as a "new pillar industry," which indicates a strategic upgrade in its significance for economic growth and industrial upgrading [10][11] - The inclusion of brain-computer interfaces in the government work report marks a significant policy shift, enhancing market focus on related fields such as neural regulation and rehabilitation robotics [11] Company Dynamics - China Biopharmaceutical has entered an exclusive licensing agreement with Sanofi for the innovative drug Roflumilast, potentially earning up to $1.53 billion, including an upfront payment of $135 million [12] - Deking Pharmaceuticals has secured a global exclusive licensing agreement for ATG-201 with UCB, which includes an upfront payment of $80 million and potential milestone payments totaling approximately $1.1 billion [13] - East China Pharmaceutical has received approval to conduct clinical trials for DR30206, a fusion protein targeting multiple pathways for non-small cell lung cancer [14] - Yahui Pharmaceutical has achieved a commercial breakthrough with the approval of APL-1702 for treating cervical intraepithelial neoplasia [15] Investment Focus - The report suggests focusing on the innovative drug supply chain and the brain-computer interface sector as key investment opportunities [4][16]

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical sector [5] Core Insights - The pharmaceutical sector has experienced a decline of 2.78% this week, ranking 17th out of 31 sectors, with a year-to-date increase of 0.1%, ranking 24th out of 31 [9] - The 2026 government work report emphasizes the importance of the biopharmaceutical industry, positioning it as a key pillar for economic growth and industrial upgrading, particularly highlighting the innovative drug sector as a core beneficiary [10][11] - The inclusion of brain-computer interfaces in the government work report marks a significant policy shift, elevating the field to a national industrial support framework, which is expected to enhance market focus on related technologies [11] Company Dynamics - China Biopharmaceutical has entered an exclusive licensing agreement with Sanofi for the innovative drug Roflumilast, with potential payments totaling up to $1.53 billion, including an upfront payment of $135 million [12] - Deking Pharmaceuticals has reached a global exclusive licensing agreement with UCB for ATG-201, with an upfront payment of $80 million and potential milestone payments totaling approximately $1.1 billion [13] - East China Pharmaceutical has received approval to conduct clinical trials for DR30206, a targeted therapy for non-small cell lung cancer [14] - Yahui Pharmaceutical has obtained approval for APL-1702, a product aimed at treating cervical intraepithelial neoplasia [15] Suggested Focus Areas - The report suggests focusing on the innovative drug supply chain and the brain-computer interface sector as key investment opportunities [4][16]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The clinical research organization (CRO) sector is experiencing a significant recovery, with new orders and backlog orders showing rapid growth. Notable companies like Medpace and Yino Science have reported substantial increases in new orders and revenue [4][14] - The price of experimental monkeys, a key material for preclinical research, has surged, indicating strong demand in the domestic innovative drug industry. The price has risen to over 130,000 yuan per monkey, up from approximately 90,000 yuan in mid-2025 [5][15] - The report emphasizes the continued recommendation of the domestic preclinical CRO sector, anticipating further acceleration in order growth [5][14] Summary by Sections Section 1: Order Growth in Preclinical CRO - Medpace signed new orders worth approximately 1.6 billion yuan in 2025, a year-on-year increase of about 45%, with revenue also growing by 12% [14][15] - Yino Science reported new orders of 1.135 billion yuan, up 38.62% year-on-year, with a backlog of 1.248 billion yuan, reflecting a 28.23% increase [14][15] - The backlog for Aopumai's subsidiary, Pengli Biology, reached 252 million yuan, a 37.68% increase year-on-year [14][15] Section 2: Market Performance - In the first week of March 2026, the pharmaceutical and biological sector fell by 2.78%, underperforming the CSI 300 index by 1.71 percentage points, ranking 17th among 31 sub-industries [6][17] - The in vitro diagnostics sector showed the highest increase, while the medical research outsourcing sector experienced the largest decline, down 4.99% [20][21] Section 3: Recommendations - The report maintains a positive outlook on the innovative drug and its supply chain, including CXO and research services, as well as emerging industries like AI and brain-machine interfaces [7] - Monthly recommendations include companies such as WuXi AppTec, CSPC Pharmaceutical Group, and Innovent Biologics, while weekly recommendations feature Aopumai, Medpace, and others [7]

Group 1: Consumer Sector Overview - Despite macroeconomic uncertainties, the consumer sector is undergoing a deep adjustment phase, with leading companies showing structural resilience and positive signals emerging in several sub-sectors [1] - The investment logic in the consumer sector has shifted from Beta-driven to Alpha-exploration, focusing on leading companies with scale barriers, brand influence, and operational efficiency [1] Group 2: Alcohol Industry - The overall sales of the liquor industry are experiencing a double-digit decline, but Kweichow Moutai is outperforming market expectations, with significant pre-holiday demand and double-digit growth in several key markets [2] - Moutai's traditional channel shipment progress is at 25%, with historical low inventory levels, leading to a steady price recovery to nearly 1700 yuan, confirming the price bottom [2] - The trend of increasing industry concentration continues, with leading brands expected to achieve year-on-year growth despite macroeconomic pressures [2] Group 3: Snack Industry - The bulk snack channel is rapidly replacing traditional retail formats, with a market size exceeding 129.7 billion yuan and a compound annual growth rate of 77.9% from 2019 to 2024 [3] - The market is highly concentrated, with leading brands "Mingming Hen Mang" and "Wancheng" holding over 75% market share, and "Mingming Hen Mang" alone accounting for approximately 43% [3] - The operational efficiency of leading companies is expected to enhance market penetration, benefiting from scale effects and further increasing industry concentration [3] Group 4: Pharmaceutical Industry - The investment opportunities in the pharmaceutical sector are increasingly structural, with the innovative drug industry chain remaining a core focus, particularly in areas like immunotherapy and small nucleic acid technology [4] - The CXO sector is experiencing a steady recovery, with improved overseas biotech financing conditions and a structural rebound in domestic CRO demand [4] - The medical device sector is expected to benefit from recovering hospital demand and improving inventory cycles, with domestic companies likely to gain market share due to expanding procurement policies [5] Group 5: Agriculture and Livestock - The pig farming industry is undergoing capacity reduction, with the number of breeding sows decreasing to 39.61 million by the end of 2025, leading to a potential price recovery supported by seasonal demand [7] - The poultry farming sector is facing tight supply due to previous overseas breeding restrictions, while the yellow feather chicken market is entering a growth phase with low historical breeding costs [7] - The planting sector is benefiting from agricultural cycle rotations and policy support, with the domestic transgenic corn industry expected to expand, favoring leading seed companies with strong R&D capabilities [7]